MedTrace Logo

Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma

NCT06643286 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2025-06-11

No results posted yet for this study

Summary

A multicentre randomised controlled trial (RCT) will be conducted to evaluate the effectiveness of the digital personalised Melanoma Survivorship Care Plan (SCP) app. A total of hundred-eighty melanoma patients (stage I and II) will be randomised to receive either the SCP Melanoma app or usual care. The app provides survivors with personalized healthcare information on diagnosis, treatment and follow-up and supportive care, tailored to their melanoma stage and phase and information needs.Through questionnaires, medical file records, patient-reported outcomes and use of medical care will be evaluated. In addition, log-data, questionnaires and interviews will be used to evaluate the process of the uptake and implementation of the digital SCP.

Conditions

  • Melanoma (Skin)
  • Melanoma, Stage II, Stage I
  • Melanoma Stage
  • Survivorship

Interventions

DEVICE

Digizorg Melanoma app

The Digizorg Melanoma app is a digital survivorship care plan, in which ellaborated information regarding diagnosis, treatment and follow-up and supportive care, adjusted to one's personal preferences and disease characteristics, is offered in the form of a mobile application.

Sponsors & Collaborators

  • BeterKeten

    collaborator UNKNOWN

  • Albert Schweitzer Hospital

    collaborator OTHER

  • Maasstad Hospital

    collaborator OTHER

  • Franciscus Gasthuis

    collaborator OTHER

  • Erasmus Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2026-09-01
Completion
2026-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06643286 on ClinicalTrials.gov